Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Optimizing COVID-19 control with asymptomatic surveillance testing in a university environment

View ORCID ProfileCara E. Brook, View ORCID ProfileGraham R. Northrup, Alexander J. Ehrenberg, the IGI Testing Consortium, View ORCID ProfileJennifer A. Doudna, View ORCID ProfileMike Boots
doi: https://doi.org/10.1101/2020.11.12.20230870
Cara E. Brook
1Department of Integrative Biology, University of California, Berkeley
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Cara E. Brook
  • For correspondence: cbrook@berkeley.edu
Graham R. Northrup
2Center for Computational Biology, College of Engineering, University of California, Berkeley
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Graham R. Northrup
Alexander J. Ehrenberg
1Department of Integrative Biology, University of California, Berkeley
3Innovative Genomics Institute, University of California, Berkeley
4Helen Wills Neuroscience Institute, University of California, Berkeley
5Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
3Innovative Genomics Institute, University of California, Berkeley
Jennifer A. Doudna
3Innovative Genomics Institute, University of California, Berkeley
6Department of Molecular and Cell Biology, University of California, Berkeley
7College of Chemistry, University of California, Berkeley
8J. David Gladstone Institutes, San Francisco, CA
9Howard Hughes Medical Institute, University of California, Berkeley
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jennifer A. Doudna
Mike Boots
1Department of Integrative Biology, University of California, Berkeley
10Department of Biosciences, University of Exeter, Penryn, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Mike Boots
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

The high proportion of transmission events derived from asymptomatic or presymptomatic infections make SARS-CoV-2, the causative agent in COVID-19, difficult to control through the traditional non-pharmaceutical interventions (NPIs) of symptom-based isolation and contact tracing. As a consequence, many US universities have developed asymptomatic surveillance testing labs, to augment existing NPIs and control outbreaks on campus. We built a stochastic branching process model of COVID-19 dynamics to advise optimal control strategies in a university environment. Our model combines behavioral interventions in the form of group size limits to deter superspreading, symptom-based isolation, and contact tracing, with asymptomatic surveillance testing. We find that behavioral interventions offer a cost-effective means of epidemic control: group size limits of six or fewer greatly reduce superspreading, and rapid isolation of symptomatic infections can halt rising epidemics, depending on the frequency of asymptomatic transmission in the population. Surveillance testing can overcome uncertainty surrounding asymptomatic infections, with the most effective approaches prioritizing frequent testing with rapid turnaround time to isolation over test sensitivity. Importantly, contact tracing amplifies population-level impacts of all infection isolations, making even delayed interventions effective. Combination of behavior-based NPIs and asymptomatic surveillance also reduces variation in daily case counts to produce more predictable epidemics. Furthermore, targeted, intensive testing of a minority of high transmission risk individuals can effectively control the COVID-19 epidemic for the surrounding population. We offer this blueprint and easy-to-implement modeling tool to other academic or professional communities navigating optimal return-to-work strategies for the 2021 year.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

CEB was funded by the Miller Institute for Basic Research at the University of California, Berkeley, the Branco Weiss Society in Science Fellowship from ETH Zurich, a DARPA PREEMPT Cooperative Grant (no. D18AC00031), and a COVID-19 Rapid Response Research grant from the Innovative Genomics Institute at the University of California, Berkeley. MB was supported by NIH grant no. R01-GM122061-03 and NSF EEID grant no. 2011109.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

No IRB approval was necessary for this study.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Within-host model updated to reflect recent publication specific to SARS-CoV-2 viral dynamics (Ke et al. 2020). Structure of superspreading events updated to reflect both heterogeneity in individual infectiousness and in contact rates.

Data Availability

All code and corresponding data are made available in the article itself and in the cited open-access Github repository.

https://zenodo.org/record/4131223

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Back to top
PreviousNext
Posted January 07, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Optimizing COVID-19 control with asymptomatic surveillance testing in a university environment
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Optimizing COVID-19 control with asymptomatic surveillance testing in a university environment
Cara E. Brook, Graham R. Northrup, Alexander J. Ehrenberg, the IGI Testing Consortium, Jennifer A. Doudna, Mike Boots
medRxiv 2020.11.12.20230870; doi: https://doi.org/10.1101/2020.11.12.20230870
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Optimizing COVID-19 control with asymptomatic surveillance testing in a university environment
Cara E. Brook, Graham R. Northrup, Alexander J. Ehrenberg, the IGI Testing Consortium, Jennifer A. Doudna, Mike Boots
medRxiv 2020.11.12.20230870; doi: https://doi.org/10.1101/2020.11.12.20230870

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Epidemiology
Subject Areas
All Articles
  • Addiction Medicine (160)
  • Allergy and Immunology (412)
  • Anesthesia (90)
  • Cardiovascular Medicine (855)
  • Dentistry and Oral Medicine (156)
  • Dermatology (97)
  • Emergency Medicine (247)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (392)
  • Epidemiology (8534)
  • Forensic Medicine (4)
  • Gastroenterology (381)
  • Genetic and Genomic Medicine (1739)
  • Geriatric Medicine (167)
  • Health Economics (370)
  • Health Informatics (1234)
  • Health Policy (618)
  • Health Systems and Quality Improvement (467)
  • Hematology (196)
  • HIV/AIDS (369)
  • Infectious Diseases (except HIV/AIDS) (10271)
  • Intensive Care and Critical Care Medicine (552)
  • Medical Education (192)
  • Medical Ethics (51)
  • Nephrology (210)
  • Neurology (1666)
  • Nursing (97)
  • Nutrition (247)
  • Obstetrics and Gynecology (325)
  • Occupational and Environmental Health (450)
  • Oncology (925)
  • Ophthalmology (262)
  • Orthopedics (100)
  • Otolaryngology (172)
  • Pain Medicine (110)
  • Palliative Medicine (40)
  • Pathology (249)
  • Pediatrics (534)
  • Pharmacology and Therapeutics (246)
  • Primary Care Research (205)
  • Psychiatry and Clinical Psychology (1757)
  • Public and Global Health (3825)
  • Radiology and Imaging (622)
  • Rehabilitation Medicine and Physical Therapy (317)
  • Respiratory Medicine (518)
  • Rheumatology (207)
  • Sexual and Reproductive Health (164)
  • Sports Medicine (156)
  • Surgery (190)
  • Toxicology (36)
  • Transplantation (100)
  • Urology (74)